GLP-1
Once-daily pill
No food restrictions

Any time. With or without food. No water restrictions.

Foundayo™ Tablets

Foundayo™ (orforglipron) is the only GLP-1 pill for weight loss that can be taken any time of day, with or without food or water restrictions. FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition.

Personalized doses

View more pricing information →

Starting at $199.99/mo

No hidden fees
No membership

Free discreet shipping
FDA-approved
Board-certified doctors

Split your payment into manageable installments with Klarna.

Get started

Important: thyroid C-cell tumor risk. Foundayo™ may cause thyroid C-cell tumors. Do not use if you or any of your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Medical consultation required to determine eligibility/if a prescription is clinically appropriate. Results may vary. For full details, important safety information, and restrictions visit: maximustribe.com/safety. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, and KwikPen® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. Maximus is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company.

Get started

Weight Loss Protocol Foundayo starting at $199.99/mo

Get started

Proven clinical outcomes.

In ATTAIN-1, a 72-week Phase 3 study of 3,127 adults with obesity (without diabetes), adults on the highest dose of Foundayo™ lost an average of 11.1% of their body weight (about 25 lb) — intent-to-treat — compared with 2.1% on placebo.

17.2 lbs

5.5 mg dose · ITT

Average 17.2 lb body weight reduction at 72 weeks (intent-to-treat).

ATTAIN-1 · Eli Lilly · 72 wk

18.9 lbs

9 mg dose · ITT

Average 18.9 lb body weight reduction at 72 weeks (intent-to-treat).

ATTAIN-1 · Eli Lilly · 72 wk

25 lbs

17.2 mg dose · ITT

Average 24.9 lb body weight reduction at 72 weeks on the highest dose (intent-to-treat). Among completers: 12.4% / 27.3 lb.

ATTAIN-1 · Eli Lilly · 72 wk

POPULATION: 3,127 adults

DURATION: 72 weeks

INDICATION: Obesity / overweight + comorbidity

POPULATION TYPE: Intent-to-treat

Get started

A small-molecule GLP-1 you take like any other pill.

Orforglipron is a small-molecule (non-peptide) GLP-1 receptor agonist. The small-molecule structure survives stomach acid and digestive enzymes without an absorption enhancer, which is why no fasting window is required. Mechanism: activates GLP-1 receptors to reduce appetite, slow gastric emptying, and lower caloric intake.

Small molecule, not a peptide

Orforglipron is a small-molecule compound, not a peptide. It survives stomach acid and digestive enzymes without an absorption enhancer.

GLP-1 receptor activation

Once absorbed, it activates GLP-1 receptors to help regulate appetite and food intake.

Six-step titration

Start at 0.8 mg, step up at least every 30 days through 2.5, 5.5, 9, 14.5, and 17.2 mg. Swallow whole, any time of day.

Side effects

Contact your provider immediately if you have these symptoms. Regular monitoring may be needed to track your response to treatment.

Common side effects may include:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain

Rare, but serious side effects may include:

Severe gastrointestinal reactions
Acute kidney injury (typically secondary to dehydration)
Hypersensitivity reactions including anaphylaxis and angioedema
Pulmonary aspiration during anesthesia or deep sedation (delayed gastric emptying)
Acute gallbladder disease
Pancreatitis
Increased resting heart rate
Suicidal behavior and ideation
Thyroid C-cell tumors (rodent data). Boxed warning class effect: contraindicated in clients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Secondary markers studied

Beyond weight, ATTAIN-1 reported metabolic improvements.

In addition to weight reduction, ATTAIN-1 reported reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses.

Reported as study observations across all doses · ATTAIN-1 · Eli Lilly · 72 wk

Waist

Reduced

Non-HDL chol.

Reduced

Triglycerides

Reduced

Systolic BP

Reduced

Is Foundayo™ right for you?

Best for people who

Adults wanting an oral GLP-1 without the Wegovy Tablets fasting ritual
Clients who do not want injections
Clients with irregular meal schedules or work patterns that make a fixed empty-stomach window difficult
Clients interested in CV-marker improvements (waist circumference, lipids, blood pressure)

Important INFORMATION

Foundayo™ may reduce the effectiveness of oral contraceptives. If you take oral contraceptives, switch to a non-oral form or add a barrier method for 30 days after starting Foundayo™ and for 30 days after each dose escalation. This is a longer interval than other GLP-1s — please discuss with your Maximus clinician.

Medical requirements

No type 2 diabetes
No history of medullary thyroid carcinoma or MEN 2 syndrome
Not currently pregnant or breastfeeding
No severe gastrointestinal disease

It's easy to get started.

Complete your evaluation

Answer a few health questions online. Takes about 5 minutes. No appointment needed, no waiting rooms.

Physician review

A board-certified physician reviews your information and determines if orforglipron is right for you.

Treatment delivered

If prescribed, your medication ships directly to your door in discreet, unmarked packaging.

Start my treatment

Weight Loss Treatment FAQs

How is Foundayo™ different from Wegovy® tablets?

Both are once-daily oral GLP-1s, but they are different molecules with different administration profiles. Wegovy® tablets contain a peptide (oral semaglutide) that requires an absorption enhancer and a strict empty-stomach routine — take with no more than 4 oz of water, wait 30 minutes before eating or drinking. Foundayo™ contains a small-molecule compound (orforglipron) that survives stomach acid on its own. You can take Foundayo™ any time of day, with or without food, with or without water restrictions. Your Maximus clinician will help determine which is the right fit for your goals and lifestyle.

What's the difference between intent-to-treat and completers?

Intent-to-treat (ITT) counts every participant who started the trial, including those who stopped early. Completers-only counts just the participants who finished the full 72 weeks. Foundayo™'s ATTAIN-1 trial reports 11.1% body weight loss (ITT) and 12.4% (completers) at the highest dose. Both are real numbers; the ITT figure is the more conservative one and is generally what regulators prefer.

I take oral contraceptives. What do I need to know?

Foundayo™ may reduce the effectiveness of oral contraceptives. If you take oral birth control, switch to a non-oral form or add a barrier method for 30 days after starting Foundayo™ and for 30 days after each dose escalation. This interval is longer than the standard 4 weeks for some other GLP-1s, so please discuss with your Maximus clinician before starting.

Can I take Foundayo™ for type 2 diabetes?

Foundayo™ is FDA-approved for chronic weight management only. Type 2 diabetes is not currently on the Foundayo™ label. Orforglipron has been studied for T2D in a separate clinical program (ACHIEVE), but that indication is not currently approved.

How long until I see results?

The ATTAIN-1 trial is reported at 72 weeks. Weight loss continues across the dose titration. Maintenance dose is 17.2 mg daily, reached after stepping through six dose strengths over several months at least 30 days apart.